Browser storage is unavailable. Keep this page open and export your collection before leaving.
Gamgee began with Rosie, founder Paul Conyngham’s dog. After surgery, chemotherapy and immunotherapy failed, Rosie was given months to live. Paul used AI and genomic analysis to identify targets in her tumour, then worked with scientists at UNSW to produce what is believed to be the first fully computationally designed mRNA cancer vaccine delivered to a dog. Following treatment, several tumours shrank significantly and her quality of life improved
Gamgee is building an end to end platform for personalised mRNA cancer vaccines for dogs. We sequence a dog’s tumour and healthy DNA, identify mutations unique to its cancer, and design a vaccine that teaches the immune system what to attack. We manage the entire process- from vet intake and tissue collection through genomic analysis, vaccine production, treatment and response monitoring
We are now turning that one off effort into a repeatable clinical system. Gamgee is running clinical trials in Australia, working with vets, oncologists and specialised laboratories, and accepting cases globally. Our goal is to make personalised cancer treatment accessible to every dog that needs it- and use each case to improve the treatment for the next
Previously Gamgee Technologies
Founder at Gamgee Technologies (YC S26), building personalised mRNA cancer vaccines. Gamgee grew out of my work using AI and genomics to help my dog Rosie fight cancer. Previously co-founded Core Intelligence, building applied AI systems across startups and enterprise, and helped grow Australia’s AI community through DSAI. Background in ML, data science and electrical and computer systems engineering
Founded 2026 · Source
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
abinitio bio is the AI-native operating platform for drug development and manufacturing.
Founders · Product · How it works
Same category · Biotech pharma
Our autonomous biodefense capabilities ensure validated point-of-care diagnostics for emerging biological threats are developed in days, not 12+ months.
Founders
Same category · Biotech pharma
Anthrogen is engineering post-modality biology. Today's modalities reflect historical contingencies in biological progress, not fundamental categories. We develop the AI systems that design modular biological machines and the…
Founders · Product
Same category · Biotech pharma
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving…
Founders · Product
Same category · Biotech pharma
Generative AI Medical Writing Solution for Biotech, Life Sciences, Pharma & Medical Devices | Artos AI. Book a demo online.
Customers · Founders · Product
Same category · Biotech pharma
Astraea is AI software for clinical trial teams. Build SDTM, ADaM and TFL outputs in your environment, with qualified experts reviewing every output.
Founders · Product · How it works
Same category · Biotech pharma
